Curis (NASDAQ:CRIS) Issues Earnings Results, Misses Expectations By $0.92 EPS

Curis (NASDAQ:CRIS) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.92), FiscalAI reports.

Here are the key takeaways from Curis’ conference call:

• Curis said its registrational Take Aim Lymphoma study in PCNSL remains on track, with the company expecting the trial to support accelerated submissions in both the U.S. and Europe after discussions with the FDA and EMA.
• The company plans to begin dosing the first five patients in its Take Aim CLL study by mid-2026, with initial data expected in December and the study designed to test whether emavusertib can deepen responses beyond BTK inhibitor monotherapy.
• Management highlighted early clinical data from the gastroesophageal cancer program, saying results in 16 evaluable patients showed a manageable toxicity profile and encouraging preliminary activity.
• Curis reported a first-quarter 2026 net loss of $24.2 million, wider than the $10.6 million loss a year ago, with the change mainly tied to warrant-liability fair value adjustments from the January PIPE financing.
• The company ended the quarter with $15 million in cash and expects available financing, including potential warrant proceeds, to fund planned operations into the second half of 2027.

Curis Stock Down 5.7%

Curis stock traded down $0.03 during mid-day trading on Wednesday, reaching $0.52. 34,202 shares of the company’s stock were exchanged, compared to its average volume of 568,689. The company has a market cap of $20.75 million, a P/E ratio of -0.44 and a beta of 3.08. Curis has a twelve month low of $0.49 and a twelve month high of $3.13. The company has a fifty day moving average of $0.69 and a 200-day moving average of $0.98.

Institutional Trading of Curis

A number of large investors have recently modified their holdings of CRIS. Maverick Capital Ltd. boosted its holdings in Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after purchasing an additional 49,554 shares during the period. Squarepoint Ops LLC grew its stake in Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 8,973 shares in the last quarter. Armistice Capital LLC increased its holdings in Curis by 8.7% during the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after purchasing an additional 78,265 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in Curis by 2,883,237.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 230,659 shares during the period. Finally, Renaissance Technologies LLC raised its position in Curis by 37.3% in the 4th quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 65,404 shares in the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Curis in a research note on Friday, March 20th. Wall Street Zen upgraded Curis to a “hold” rating in a report on Saturday, March 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.00.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.